| scholarly article | Q13442814 |
| P50 | author | Elena Gonzalez-Rey | Q56754174 |
| Alejo Chorny | Q42589937 | ||
| Mario Delgado | Q42766954 | ||
| P2093 | author name string | Doina Ganea | |
| Amelia Fernandez-Martin | |||
| P2860 | cites work | A sudden decline in active membrane-bound TGF-beta impairs both T regulatory cell function and protection against autoimmune diabetes. | Q52064429 |
| Autoreactive human peripheral blood CD8+ T cells with a regulatory phenotype and function. | Q54641462 | ||
| CD40-deficient dendritic cells producing interleukin-10, but not interleukin-12, induce T-cell hyporesponsiveness in vitro and prevent acute allograft rejection | Q73128939 | ||
| Regulatory dendritic cells protect mice from murine acute graft-versus-host disease and leukemia relapse | Q73153290 | ||
| Characterization of Dendritic Cells that Induce Tolerance and T Regulatory 1 Cell Differentiation In Vivo | Q73407790 | ||
| Human peripheral blood monocyte-derived interleukin-10-induced semi-mature dendritic cells induce anergic CD4(+) and CD8(+) T cells via presentation of the internalized soluble antigen and cross-presentation of the phagocytosed necrotic cellular fra | Q74684911 | ||
| RelB is essential for the development of myeloid-related CD8alpha- dendritic cells but not of lymphoid-related CD8alpha+ dendritic cells | Q77769122 | ||
| Antigen-specific suppression of a primed immune response by dendritic cells mediated by regulatory T cells secreting interleukin-10 | Q78804319 | ||
| The many faces of VIP in neuroimmunology: a cytokine rather a neuropeptide? | Q80500671 | ||
| Cytotoxic T lymphocyte-associated antigen 4 plays an essential role in the function of CD25(+)CD4(+) regulatory cells that control intestinal inflammation | Q24676080 | ||
| Lymphoproliferative disorders with early lethality in mice deficient in Ctla-4 | Q28284177 | ||
| Immunobiology of dendritic cells | Q29547465 | ||
| Tolerogenic dendritic cells | Q29618755 | ||
| A CD4+ T-cell subset inhibits antigen-specific T-cell responses and prevents colitis | Q29619339 | ||
| CD4+CD25+ immunoregulatory T cells suppress polyclonal T cell activation in vitro by inhibiting interleukin 2 production | Q29619536 | ||
| Dendritic cells induce peripheral T cell unresponsiveness under steady state conditions in vivo | Q30080006 | ||
| Vasoactive intestinal peptide induces regulatory dendritic cells with therapeutic effects on autoimmune disorders. | Q34015933 | ||
| The role of CD40 in peripheral T cell tolerance and immunity | Q34067144 | ||
| Differentiation of T regulatory cells by immature dendritic cells | Q34157114 | ||
| The significance of vasoactive intestinal peptide in immunomodulation | Q34323695 | ||
| Immunologic self-tolerance maintained by CD25(+)CD4(+) regulatory T cells constitutively expressing cytotoxic T lymphocyte-associated antigen 4. | Q34509694 | ||
| Transient blockade of CD40 ligand dissociates pathogenic from protective mucosal immunity | Q34786965 | ||
| Dendritic cells: regulators of alloimmunity and opportunities for tolerance induction | Q35583516 | ||
| Dendritic cells: emerging pharmacological targets of immunosuppressive drugs | Q35620073 | ||
| Regulatory T cells and tolerogenic dendritic cells: from basic biology to clinical applications | Q35826893 | ||
| Vasoactive intestinal peptide induces regulatory dendritic cells that prevent acute graft-versus-host disease while maintaining the graft-versus-tumor response | Q35849658 | ||
| A critical role for the RelA subunit of nuclear factor kappaB in regulation of multiple immune-response genes and in Fas-induced cell death | Q36368150 | ||
| Human plasmacytoid dendritic cells activated by CpG oligodeoxynucleotides induce the generation of CD4+CD25+ regulatory T cells | Q38336314 | ||
| Overlap between molecular markers expressed by naturally occurring CD4+CD25+ regulatory T cells and antigen specific CD4+CD25+ and CD8+CD28- T suppressor cells | Q40489553 | ||
| Neuropilin-1: a surface marker of regulatory T cells | Q40584286 | ||
| CD8(+)CD28(-) T suppressor cells represent a distinct subset in a heterogeneous population | Q40818639 | ||
| The emerging role of CTLA-4 as an immune attenuator | Q41630509 | ||
| Induction of interleukin 10-producing, nonproliferating CD4(+) T cells with regulatory properties by repetitive stimulation with allogeneic immature human dendritic cells | Q42944333 | ||
| VIP/PACAP oppositely affects immature and mature dendritic cell expression of CD80/CD86 and the stimulatory activity for CD4(+) T cells | Q44799759 | ||
| Analysis of regulatory CD8 T cells in Qa-1-deficient mice | Q44903222 | ||
| Modified myeloid dendritic cells act as regulatory dendritic cells to induce anergic and regulatory T cells | Q44986020 | ||
| Identification of a novel natural regulatory CD8 T-cell subset and analysis of its mechanism of regulation. | Q44991530 | ||
| Antigen-bearing immature dendritic cells induce peptide-specific CD8(+) regulatory T cells in vivo in humans | Q45221904 | ||
| The neuropeptide vasoactive intestinal peptide generates tolerogenic dendritic cells | Q46815019 | ||
| Nonantigen specific CD8+ T suppressor lymphocytes originate from CD8+CD28- T cells and inhibit both T-cell proliferation and CTL function. | Q51032192 | ||
| P433 | issue | 9 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | dendritic cell | Q506253 |
| P304 | page(s) | 3632-3638 | |
| P577 | publication date | 2006-01-05 | |
| P1433 | published in | Blood | Q885070 |
| P1476 | title | Vasoactive intestinal peptide generates human tolerogenic dendritic cells that induce CD4 and CD8 regulatory T cells | |
| P478 | volume | 107 |
| Q92156296 | A Clinical Approach for the Use of VIP Axis in Inflammatory and Autoimmune Diseases |
| Q62593836 | A functional polymorphism of the vasoactive intestinal peptide receptor 1 gene correlates with the presence of HLA-B *2705 in Sardinia |
| Q37235176 | A homodimeric complex of HLA-G on normal trophoblast cells modulates antigen-presenting cells via LILRB1. |
| Q37873407 | Activated immune cells in Parkinson's disease |
| Q35753939 | Acupuncture: Emerging evidence for its use as an analgesic (Review). |
| Q34071942 | Adaptive immune regulation of glial homeostasis as an immunization strategy for neurodegenerative diseases |
| Q38714704 | Administration of a vasoactive intestinal peptide antagonist enhances the autologous anti-leukemia T cell response in murine models of acute leukemia |
| Q80512153 | Anti-CD25 treatment and FOXP3-positive regulatory T cells in heart transplantation |
| Q54573052 | Association of neuropeptides with Th1/Th2 balance and allergic sensitization in children. |
| Q48004729 | Autologous tolerogenic dendritic cells derived from monocytes of systemic lupus erythematosus patients and healthy donors show a stable and immunosuppressive phenotype. |
| Q24648682 | Binding immunoglobulin protein-treated peripheral blood monocyte-derived dendritic cells are refractory to maturation and induce regulatory T-cell development |
| Q43760316 | CD4+CD25+ Treg induction by an HSP60-derived peptide SJMHE1 from Schistosoma japonicum is TLR2 dependent. |
| Q39971245 | Cholera toxin B subunit promotes the induction of regulatory T cells by preventing human dendritic cell maturation |
| Q34982085 | Dendritic cell control of tolerogenic responses |
| Q34004810 | Dendritic cell-regulatory T-cell interactions control self-directed immunity |
| Q36014986 | Dendritic cells and regulation of graft-versus-host disease and graft-versus-leukemia activity |
| Q37945301 | Dendritic cells in the pathogenesis and treatment of human diseases: a Janus Bifrons? |
| Q38114071 | Dendritic cells: cellular mediators for immunological tolerance |
| Q53128283 | Does autoimmunity of endogenous vasoactive neuropeptides cause retinopathy in humans? |
| Q36923640 | Emerging neuropeptide targets in inflammation: NPY and VIP |
| Q36969911 | Emerging roles of vasoactive intestinal peptide: a new approach for autoimmune therapy |
| Q37191369 | Endogenous anti-inflammatory neuropeptides and pro-resolving lipid mediators: a new therapeutic approach for immune disorders |
| Q51742003 | HIV-based lentivirus-mediated vasoactive intestinal peptide gene delivery protects against DIO animal model of Type 2 diabetes. |
| Q37787980 | Host‐bacteria interactions in the intestine: homeostasis to chronic inflammation |
| Q34631825 | How tolerogenic dendritic cells induce regulatory T cells |
| Q43981293 | Immune modulation in gastrointestinal disorders: new opportunities for therapeutic peptides? |
| Q37552024 | Immunomodulation of innate immune responses by vasoactive intestinal peptide (VIP): its therapeutic potential in inflammatory disease. |
| Q27687406 | Immunotherapy with myeloid cells for tolerance induction |
| Q58707479 | Induction of Tolerogenic Dendritic Cells by Endogenous Biomolecules: An Update |
| Q42110748 | LPS activation is required for migratory activity and antigen presentation by tolerogenic dendritic cells. |
| Q35886882 | Lipopolysaccharide-pretreated plasmacytoid dendritic cells ameliorate experimental chronic kidney disease |
| Q89517312 | Natural and Induced Tolerogenic Dendritic Cells |
| Q38868323 | Neuropeptide substance P and the immune response |
| Q37898396 | Neuropeptides as pleiotropic modulators of the immune response. |
| Q36158715 | Neuropeptides: keeping the balance between pathogen immunity and immune tolerance |
| Q83823328 | New insights into the role of VIP on the ratio of T-cell subsets during the development of autoimmune diabetes |
| Q36498879 | Ocular and systemic bio-distribution of rhodamine-conjugated liposomes loaded with VIP injected into the vitreous of Lewis rats. |
| Q38026029 | Pathogenesis of achalasia cardia |
| Q37957125 | Pathways towards an effective immunotherapy for Parkinson's disease |
| Q36709854 | Pharmacological inhibition of VIP signaling enhances antiviral immunity and improves survival in murine cytomegalovirus-infected allogeneic bone marrow transplant recipients. |
| Q38694548 | Pituitary adenylate cyclase-activating polypeptide (PACAP) contributes to the proliferation of hematopoietic progenitor cells in murine bone marrow via PACAP-specific receptor. |
| Q35094028 | Prospects of statins in Parkinson disease |
| Q37074087 | Protected graft copolymer excipient leads to a higher acute maximum tolerated dose and extends residence time of vasoactive intestinal Peptide significantly better than sterically stabilized micelles |
| Q38246755 | Recent advances on cellular therapies and immune modulators for graft-versus-host disease |
| Q36693973 | Regulation of dendritic cell differentiation by vasoactive intestinal peptide: therapeutic applications on autoimmunity and transplantation |
| Q36691091 | Regulation of immune tolerance by anti-inflammatory neuropeptides |
| Q37581433 | Regulation of the mucosal phenotype in dendritic cells by PPARγ: role of tissue microenvironment |
| Q40049981 | Regulatory Dendritic Cells |
| Q30493249 | Regulatory T cells attenuate Th17 cell-mediated nigrostriatal dopaminergic neurodegeneration in a model of Parkinson's disease |
| Q38095964 | Regulatory T-cell immunotherapy for allogeneic hematopoietic stem-cell transplantation |
| Q26866216 | Regulatory dendritic cells for immunotherapy in immunologic diseases |
| Q37895356 | Role of dendritic cells in the induction of regulatory T cells |
| Q34408962 | Suppression of antigen-specific adaptive immunity by IL-37 via induction of tolerogenic dendritic cells |
| Q38167815 | T regulatory cells in childhood arthritis--novel insights |
| Q35295564 | Targeting VIP and PACAP receptor signalling: new therapeutic strategies in multiple sclerosis |
| Q40715358 | The Complement Inhibitor Factor H Generates an Anti-Inflammatory and Tolerogenic State in Monocyte-Derived Dendritic Cells |
| Q26774660 | The Neuromodulation of the Intestinal Immune System and Its Relevance in Inflammatory Bowel Disease |
| Q33656489 | The expression of vasoactive intestinal peptide receptor 1 is negatively modulated by microRNA 525-5p |
| Q49242675 | Tolerance through Education: How Tolerogenic Dendritic Cells Shape Immunity. |
| Q44367035 | Tolerogenic dendritic cells impede priming of naïve CD8⁺ T cells and deplete memory CD8⁺ T cells |
| Q34602052 | Translational mini-review series on Toll-like receptors: Toll-like receptor ligands as novel pharmaceuticals for allergic disorders |
| Q37750140 | Treating arthritis by immunomodulation: is there a role for regulatory T cells? |
| Q36830470 | Tuning immune tolerance with vasoactive intestinal peptide: a new therapeutic approach for immune disorders |
| Q47121682 | Update on Dendritic Cell-Induced Immunological and Clinical Tolerance. |
| Q37054934 | VPAC1 receptor (Vipr1)-deficient mice exhibit ameliorated experimental autoimmune encephalomyelitis, with specific deficits in the effector stage |
| Q34765538 | VPAC2 (vasoactive intestinal peptide receptor type 2) receptor deficient mice develop exacerbated experimental autoimmune encephalomyelitis with increased Th1/Th17 and reduced Th2/Treg responses. |
| Q37729146 | Vaccines as early therapeutic interventions for cancer therapy: neutralising the immunosuppressive tumour environment and increasing T cell avidity may lead to improved responses |
| Q35849658 | Vasoactive intestinal peptide induces regulatory dendritic cells that prevent acute graft-versus-host disease while maintaining the graft-versus-tumor response |
| Q34238010 | Vasoactive intestinal peptide: a neuropeptide with pleiotropic immune functions |
Search more.